BCM
AMED

BlueCrest Capital Management’s Amedisys AMED Stock Holding History

BlueCrest Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,951
Closed -$364K – 424
2019
Q1 		$364K Buy
+2,951
New +$370K 0.01% 613
2018
Q4 		– Sell
-3,456
Closed -$432K – 851
2018
Q3 		$432K Buy
+3,456
New +$382K 0.01% 836
2018
Q2 		– Sell
-4,428
Closed -$267K – 1462
2018
Q1 		$267K Buy
+4,428
New +$252K 0.01% 1128

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

BlueCrest Capital Management's AMED Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Amedisys (AMED) in Q2 2019, closing a stake of 2,951 shares — an estimated $364K sold.

BlueCrest Capital Management first reported a position in AMED in Q1 2018 and held it in 3 quarters. The position peaked at $432K in Q3 2018. 285 funds tracked by Wall St. Rank hold AMED as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Amedisys position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 2,951 Amedisys shares in Q2 2019, an estimated $364K.
  • BlueCrest Capital Management first reported a position in Amedisys in Q1 2018 and held it in 3 quarters.
  • BlueCrest Capital Management's Amedisys position peaked at $432K in Q3 2018.
  • 285 funds tracked by Wall St. Rank held Amedisys as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.